Logo

Amgen Reports the US FDA's Acceptance of sNDA for Review of Otezla (apremilast) to Treat Mild-To-Moderate Plaque Psoriasis

Share this
Amgen Reports the US FDA's Acceptance of sNDA for Review of Otezla (apremilast) to Treat Mild-To-Moderate Plaque Psoriasis

Amgen Reports the US FDA's Acceptance of sNDA for Review of Otezla (apremilast) to Treat Mild-To-Moderate Plaque Psoriasis

Shots:

  • The acceptance is based on a P-III ADVANCE trial assessing the efficacy of Otezla (30 mg- bid) vs PBO in 595 patients in a ratio (1:1) with mild-to-moderate plaque psoriasis for the first 16wks. All patients then received Otezla during an OLE phase through week 32.
  • Results: @16wks.- improvement in its 1EPs of sPGA score; achieve 2EPs i.e- 75% improvement in BSA- change in PASI score- clinical improvements were maintained @32wks. The anticipated PDUFA date is Dec 19- 2021
  • Otezla is a selective PDE4 inhibitor and is approved for the mod. to sev. plaque psoriasis who are candidates for phototherapy or systemic therapy- active PsA- and oral ulcers associated with Behçet’s Disease

  Ref: PRNewswire | Image: Amgen

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions